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INTRODUCTION
Secondary ovarian involvement by malignant lymphoma is
well recognized with a frequency as high as 20-30% in some
autopsy series (1). Primary ovarian lymphoma (POL) is quite
rare and accounts for less than 0.8-1% of all lymphoma involv-
ing the ovary (2, 3). The incidence of autoimmune hemolytic
anemia (AIHA) is known to be approximately 3% in patients
with non-Hodgkin’ s lymphoma (NHL) (4, 5).
We report a case of POL and AIHA successfully managed
with a combination of surgery and adjuvant chemotherapy.
CASE REPORT
In September 2001, a 29-yr-old woman with low abdominal
pain visited our emergency room. Laboratory data showed a
hemoglobin level of 6.7 g/dL and a reticulocyte count of 7.2%.
Serum direct/indirect bilirubin levels were 3.2/1.0 mg/dL.
The lactate dehydrogenase level was 2,450 U/L. The direct and
indirect Coomb’ s tests were positive. The erythrocyte sedimen-
tation rate was 30 mm/hr. The C-reactive protein was not in-
creased. The anti-nuclear antibody and anti-double-stranded
DNA antibody were absent. The complement level was nor-
mal. Peripheral blood smear showed a normocytic normochro-
mic anemia with red blood cell agglutination. The pelvis MRI
showed a well marginated pelvic cavity mass (Fig. 1). We sus-
pected a myoma or a solid adnexal tumor accompanied by
AIHA. We concluded that AIHA should be treated first, and
then exploratory laparotomy be needed.
The patient was treated with prednisolone 1 mg/kg daily.
The dosage of prednisolone was gradually tapered to 7.5 mg
over the next 3 months. In November 2001, exploratory laparo-
tomy revealed a 14 cm sized multinodular mass involving the
right ovary. The mass was not adherent to the adjacent organs
and was removed with the right Fallopian tube without diffi-
culty. The left Fallopian tube, ovary, uterus, and kidneys were
normal. The liver, diaphragm, and omentum were not involved.
No enlarged lymph node, more than 1 cm size, was identi-
fied in the abdomen. Peritoneal washing was performed and
the pathology finding revealed no abnormal cells. On gross
examination, the right ovarian mass measured 14×10×9
cm. The cut surface of the ovarian mass revealed a solid, mul-
tilobulated tumor (Fig. 2). Microscopic examination revealed
complete replacement of the ovarian tissue by sheets of neo-
plastic cells (Fig. 3). Paraffin immunoperoxidase studies sh-
owed strong positive marking of the neoplastic cell for CD45
(LCA) and CD20 (L-26).
Therefore, a diagnosis of NHL with the type of diffuse large
B-cell was possible. The chest, abdomen, and neck comput-
erized tomography scan were performed postoperatively and
there were no evidence of abnormal lymph node enlargement.
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Autoimmune Hemolytic Anemia in a Patient with Primary Ovarian
Non-Hodgkin's Lymphoma
The primary ovarian lymphoma is a rare disease with poor prognosis. The inci-
dence of autoimmune hemolytic anemia in patients with non-Hodgkin’s lymphoma
is estimated at 3%. However, a substantial portion of the previously reported
cases of ovarian lymphoma actually represented ovarian involvement by more dif-
fuse lymphomatous process. If stringent criteria are used for case selection, true
primary ovarian lymphoma usually carries a favorable prognosis. We present a
primary malignant lymphoma of ovary accompanied by autoimmune hemolytic
anemia in a 29-yr- old patient. After ablative surgery, the hemoglobin level and the
reticulocyte count were normalized. One year following surgery and chemothera-
py, the patient is alive and disease free.
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There were no specific abnormality on a 67Gallium scan, endo-
scopy, and bone marrow biopsy. Serum protein electrophore-
sis showed normal pattern.
We stopped prednisolone but the hemoglobin level and
the reticulocyte count were normalized (Table 1). The direct
and indirect Coomb’ s test were converted to negative. In De-
cember 2001, the patient was treated with a combination of
chemotherapeutic agents including vincristine, adriamycin,
cyclophosphamide, and prednisolone with no major side-effect.
One year following surgery and six cycles of chemotherapy,
the patient alive and anemia free (Table 1).
DISCUSSION
POL is a rare disease and many authors have been question-
able about the existence of disease entity. Since the normal
ovary is devoid of any lymphoid tissue, other sources, such as
lymphoid aggregates in the ovarian hilum or chronic inflam-
matory cells in the ovary in response to ovarian lesions, such
as pelvic inflammatory disease or endometriosis, have been
cited as possible origins for POL (6). More recent studies have
found benign lymphoid aggregates in approximately half of
normal ovaries (7). It is hypothetically possible that on rare
occasion these lymphoid aggregates may undergo malignant
transformation, giving to a POL (6).
In the past, the diagnosis of POL required only substanti-
ation by histologic examination of the ovarian lesion. Many
cases of POL reported in larger series were actually cases of
Fig. 1. Pelvis MRI showing a large mass in the pelvic cavity.
Fig. 3. Medium-power view of the lesion shows an organoid with
small rounded nests of tumor cells surrounded by thin fibrous sep-
tae (hematoxylin and eosin, ×100).
Fig. 2. The cut surface of the right ovarian lesion shows a solid, gray
white to yellow, multilobulated tumor.
*, At the time of initial diagnosis; 
� , After laparotomy; 
� , After six cycles of
chemotherapy.
September
2001*
November
2001
�
May
2002
�
Hemoglobin (g/dL) 6.7 9.8 11.2
Reticulocyte (%) 7.2 1.5 0.6
Lactate dehydrogenase (U/L) 2450 697 512
Total/direct bilirubin (mg/dL) 3.2/1.0 0.3/0.1 0.5/0.2
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malignant lymphoma with ovarian enlargement as the pre-
senting symptom (8, 9). All types of lymphomas have been
represented, mostly NHL with rare cases of Hodgkin’ s dis-
ease included (2, 9, 10). Only a few cases of POL have been
reported, and the prognosis was generally poor with survival
rates ranging from 7 to 38% (2, 11).
Fox et al. (12) proposed the following criteria for the diag-
nosis of POL: The lymphoma is clinically confined to the
ovary at the time of diagnosis and full investigations fail to
reveal evidence of lymphoma elsewhere. A lymphoma can
still be considered to be of ovarian origin if spread has occurred
to the immediately adjacent lymph nodes or if there has been
direct spread infiltrating the immediately adjacent structures.
The peripheral blood and bone marrow should not contain
any abnormal cell. If further lymphomatous lesions occur at
sites remote from the ovary, at least several months should
have elapsed between the appearance of the ovarian and extra-
ovarian lesions. If these stringent criteria are applied, POL be-
comes vanishingly rare, and only 20 cases have been reported
in the world literature. Skodras et al. (13) reviewed the liter-
ature and found 15 cases of ovarian lymphoma meeting the
above criteria. The patients’ ages ranged from 2 to 63 yr (mean
age, 37.7 yr). Nine patients were found to have diffuse large
cell or mixed large and small cell lymphoma. Following treat-
ment that consisted of ablative surgery with or without adju-
vant chemotherapy, all 15 patients were alive with no evidence
of disease except one who developed multiple local recurrences.
Our patients met the criteria for POL and had a favorable
outcome similar to those reviewed in this series.
The process of rearrangement of the immunoglobulin and
T-cell receptor gene segments in the DNA of precursor lym-
phocytes not only allows the formation of a large number of
complete genes, but also creates the potential for the generation
of autoreactive lymphocytes on daily basis. Failure to elimi-
nate these autoreactive cells or the breakdown in the mecha-
nisms that prevent their expansion may lead to several autoim-
mune manifestations. Therefore, it is not surprising that pa-
tients with a tumor of the immune system such as B- or T-cell
NHL are at risk of developing antibodies against hematopoi-
etic cells or other tissues (4, 14, 15). Sallah et al. (5) reported
that the patients with NHL/AIHA have poor prognosis. The
impact of this finding on the recommendation that can be
offered based on this report is two fold. First, consideration
should be given for the inclusion of immunomodulators such
as cyclosporine or other agents in the treatment regimens of
patients with NHL who develop AIHA with an emphasis on
achieving rapid resolution of the hemolytic process. Second,
AIHA should be included in the risk-stratification of patients
with NHL as an adverse prognotic sign. Our patient was re-
solved from a AIHA by a combination of prednisolone and
surgery.
In summary, we report a case of POL accompanied by
AIHA, which was successfully managed with a combination
of surgery and chemotherapy.
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